Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14443433 | 0.79 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL341265 | 0.79 | PKM (0.38) | — | |
| SCHEMBL499275 | 0.76 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL15584545 | 0.76 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL24876166 | 0.76 | CA14 (0.39) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL342403 | 0.75 | CHRM1 (0.35) | — | |
| SCHEMBL10260946 | 0.74 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL15085762 | 0.74 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CTSKCA14 | |
| SCHEMBL16825071 | 0.74 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL5962320 | 0.74 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026336-B1 | 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-04-11 | — | — | US | disclosed |
| EP-1232153-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | disclosed |